- Identifying mutations in the BRCA1, BRCA2 genes has both benefits for ovarian cancer patients, who can be used as targeted therapy with PARP inhibitors to bring high treatment efficiency and benefits to patients relatives, who were consulted for genetic testing to detect the possibility of carrying BRCA1, BRCA2 genes mutations and appropriate guidance on screening and prevention of breast and ovarian cancer.